✦ LIBER ✦

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

✍ Scribed by Coleman, R.; Sill, M.; Aghajanian, C.; Gray, H.; Tewari, K.; Rubin, S.; Rutherford, T.; Chan, J.; Swisher, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of mifepristone in

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

A phase II evaluation of AMG 102 (rilotu

✍ Martin, Lainie P.; Sill, Michael; Shahin, Mark S.; Powell, Matthew; DiSilvestro, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 246 KB

Phase II evaluation of dasatinib in the

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

A phase II evaluation of lapatinib in th

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB

A phase II study of a urokinase-derived

✍ Michael A. Gold; William E. Brady; Heather A. Lankes; Peter G. Rose; Joseph L. K 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 257 KB

A phase II evaluation of belinostat and

✍ Don S. Dizon; John A. Blessing; Richard T. Penson; Richard D. Drake; Joan L. Wal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 197 KB